Sign in Subscribe

liquid-biopsy

A collection of 68 issues

Symptom Identification Critical for Adults 18-44

Skip to content The CRC Digest Symptom Identification Critical for Adults 18-44 Adults under 45 without access to average-risk screening require a well-defined system for symptom identification and workup to avoid diagnostic delays and worse outcomes. (Cancer Epidemiology, Biomarkers & Prevention) This content is informational only and does not constitute

FIT Remains Cornerstone of Population-Based CRC Screening

Skip to content The CRC Digest ▪ SCREENING FIT Remains Cornerstone of Population-Based CRC Screening Fecal immunochemical testing (FIT) continues to be the foundation of organized colorectal cancer screening programs due to its noninvasive nature, affordability, and proven mortality reduction, though stool DNA tests may serve as complementary options in hybrid

Study Examines Symptoms as Diagnostic Indicators in Adults Under 45

Skip to content The CRC Digest ▪ SCREENING Study Examines Symptoms as Diagnostic Indicators in Adults Under 45 (Cancer Epidemiology, Biomarkers & Prevention) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com

Circulating Tumor DNA Predicts Recurrence Risk in Stage III Colorectal Cancer

Skip to content The CRC Digest ◇ RESEARCH Circulating Tumor DNA Predicts Recurrence Risk in Stage III Colorectal Cancer A systematic review and meta-analysis found that circulating tumor DNA (ctDNA) testing can help predict which stage III colorectal cancer patients are at higher risk of recurrence after surgery. (Clinical Colorectal Cancer)

Liquid Biopsy Detects ctDNA in 95% of Metastatic CRC Patients

Skip to content The CRC Digest ▸ TREATMENT Liquid Biopsy Detects ctDNA in 95% of Metastatic CRC Patients A Japanese single-center study using Guardant360 CDx found circulating tumor DNA in 18 of 19 metastatic colorectal cancer patients, with a median turnaround time of 11 days and pathogenic alterations identified in 79%

Liquid Biopsy Guides HER2 Therapy Rechallenge in Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT Liquid Biopsy Guides HER2 Therapy Rechallenge in Metastatic CRC A study found that liquid biopsy can guide rechallenge with anti-HER2 therapy in patients with HER2-amplified metastatic colorectal cancer. (JCO Precision Oncology) This content is informational only and does not constitute medical advice. Always

Dynamic ctDNA Methylation Monitoring Guides Postoperative Surveillance in FIND Trial

Skip to content The CRC Digest ◆ TRIAL DATA Dynamic ctDNA Methylation Monitoring Guides Postoperative Surveillance in FIND Trial A prospective, randomized phase III trial tested whether circulating tumor DNA methylation monitoring can guide postoperative surveillance in nonmetastatic colorectal cancer patients. (Journal of Clinical Oncology) This content is informational only and

Gut microbiome signatures show promise for non-invasive detection of colorectal neoplasia

Skip to content The CRC Digest ▪ SCREENING Gut microbiome signatures show promise for non-invasive detection of colorectal neoplasia Multinational metagenomic studies have identified reproducible microbial signatures associated with CRC, offering a potential alternative to current stool-based tests that have limited sensitivity for adenoma detection. (Journal of Gastroenterology) This content is

Phase 3 FIND trial shows ctDNA-guided surveillance detects recurrence earlier than standard CT scans after curative surgery

Skip to content The CRC Digest ▪ SCREENING Phase 3 FIND trial shows ctDNA-guided surveillance detects recurrence earlier than standard CT scans after curative surgery The randomized trial found that circulating tumor DNA methylation monitoring identified recurrent metastatic disease with a more favorable and potentially resectable anatomical profile, significantly increasing the

Liquid biopsy may guide HER2-targeted therapy rechallenge in metastatic disease

Skip to content The CRC Digest ▸ TREATMENT Liquid biopsy may guide HER2-targeted therapy rechallenge in metastatic disease Real-world data suggest that monitoring HER2 amplification through liquid biopsy can help identify patients with HER2-amplified metastatic colorectal cancer who may benefit from rechallenge with anti-HER2 therapy. (JCO Precision Oncology) This content is